The TeraBioStation, a rapid one-stop solution, revolutionizes public testing worldwide. In response to the COVID-19 pandemic, TERA.Bio, a fully owned subsidiary of TERA, focuses exclusively on commercializing its breath mass-screening solution. This solution aims to ‘clear’ healthy populations in their daily activities.

Terahertz waves, with their unique ability to scan and identify chemical and biological biomarkers in breath—including proteins associated with infectious viruses—play a pivotal role. Breath collection can be easily and ethically administered to large groups of people in high-traffic areas and populated places.

Studies have identified over 3,000 Volatile Organic Compounds (VOCs) present in breath alongside respiratory aerosols. These VOCs, often referred to as biomarkers, offer valuable insights into an individual’s overall health. They serve as indicators of disease onset, variants, and progression. Until now, efficient breath screening for viruses faced technological challenges, such as achieving sufficient sensitivity levels.

The TERA.Bio Tests is a ~1-minute non-invasive clearance test that analyzes breath aerosols and VOCs of viruses, including COVID-19. Real-time results are displayed directly on the TeraBioStation, subject to the individual’s consent. These tests have been demonstrated in clinical trials in Israel, Latin America, Asia, USA (pending FDA approval), UAE and Europe (CE Mark approved).